Hyderabad, Oct. 23 -- Dr Reddy's Laboratories Ltd on Friday reported a 36 per cent year-on-year decline in profit attributable to equity holders at Rs 925 crore for the second quarter ended September 30, 2026, against Rs 1,437.2 crore in the corresponding period last year, mainly due to lower sales of lenalidomide in North America.
The Hyderabad-based pharmaceutical major's consolidated revenue declined 1.5 per cent to Rs 8,670.8 crore during the quarter from Rs 8,805.1 crore in Q2FY26.
However, revenue increased 7.4 per cent sequentially from Rs 8,070.5 crore in the preceding quarter, the pharma company said in release here.
Earnings before interest, tax, depreciation and amortisation (EBITDA) fell 24 per cent year-on-year to Rs 1,782.8...